Spire Wealth Management bought a new position in Novavax, Inc. (NASDAQ:NVAX – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange ...

Shares of Novavax Inc. NVAX slipped 1.69% to $8.13 Friday, on what proved to be an all-around poor trading session for the ...

The stock's fall snapped a two-day winning streak.

After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...

Bullish option flow detected in Novavax (NVAX) with 5,702 calls trading, 1.1x expected, and implied vol increasing almost 10 points to 99.21%. 1/31 weekly 10 calls and 1/31 weekly 9.5 calls are ...

Novavax (NVAX) is one of the stocks most watched ... While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to ...

Novavax (NVAX) closed at $8.19 in the latest trading session, marking a +0.74% move from the prior day. This move outpaced the S&P 500's daily gain of 0.67%. At the same time, the Dow added 0.38%, and ...

So, it's important to know a company's potential revenue growth. For Novavax, the consensus sales estimate for the current quarter of $90.72 million indicates a year-over-year change of -68.9%.

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced progress in Q4 2024 advancing its corporate growth strategy through ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Things were looking up for Novavax stock after the FDA resolved a clinical hold. But the company trimmed its outlook. Is NVAX stock a sell in December 2024? Novavax, Inc. (Nasdaq: NVAX), a global ...